Faron Pharmaceuticals - Innovatiivisia lääketieteen ratkaisuja (Osa 2)

Lind and Syrjälä’s sales really reek of a directed share issue. I wonder if a new major player has been found who would sink tens of millions into Faron? Hard to believe that we could buy much additional time through financing with only Lind and Syrjälä’s efforts if the price tag for the F2b/3 is €50M🤔

2 Likes